CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2015, and highlighted recent progress in advancing its pipeline.
“The second quarter of 2015 and recent period were marked by tremendous progress in our efforts to bring innovative medicines to patients, as we execute on our ‘Alnylam 2020’ strategy.
Help employers find you! Check out all the jobs and post your resume.
